Oncology Drugs Market By Indication (Breast Cancer, Prostate Cancer, Basal Cell Cancer, Skin Cancer (Non-Melanoma), Colorectal Cancer, Lung Cancer, Renal Cancer, Bladder Cancer, Lymphoma and Others), By Treatment (Drug Therapies (Antimetabolites, Antitumor Antibiotics, Asparagine-Specific Enzymes, Bisphosphonates and Biosimilars, DNA-Damaging Agents (Antineoplastics) and Alkylating Agents, Inhibitors(DNA-Repair Enzyme Inhibitors, Histone Deacetylase Inhibitors, Janus-Associated Kinase (JAK) Inhibitors, Proteasome Inhibitors, Tyrosine Kinase Inhibitors, PD-1 and PD-L1 Inhibitors and Others)), Surgery (Open Surgery and Minimally Invasive Surgery), Radiation Therapy, Chemotherapy, Immunotherapy (Chimeric Antigen Receptor (CAR) T-Cell Therapy, Cytokine Treatment, Donor Lymphocyte Infusion, Monoclonal Antibody Treatment and Others), Targeted Therapy, Hormone Therapy, Stem Cell Transplant (Autologous Stem Cell Transplantation, Allogeneic Stem Cell Transplantation, Reduced-Intensity Allogeneic Stem Cell Transplantation, Graft-Versus-Host Disease), Precision Medicine and Others), By Region (U.S., Canada, Mexico, Rest of North America, France, UK, Germany, Spain, Italy, Nordic Countries, Benelux Union, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Rest of Asia Pacific, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of MEA, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2019 – 2027
Report ID :AMI-273 | Category : Healthcare | Published Date : September, 2019 | Pages : 600 | Format :PDF